A. Michael Lincoff, MD

Article

Dual antiplatelet therapy for acute coronary syndromes: How long to continue?

Author:: A. Michael Lincoff, MD

Publish date: September 1, 2016

After drug-eluting stent placement, at least 12 months of dual antiplatelet therapy is recommended. Would longer be better?

Article

Should patients with stable ischemic heart disease undergo revascularization?

Author:: A. Michael Lincoff, MD

Publish date: August 1, 2016

The benefit is much less clear for stable disease than for acute coronary syndromes.

Article

Managing acute coronary syndromes: Decades of progress

Author:: A. Michael Lincoff, MD

Publish date: April 1, 2014

In managing acute coronary syndromes, physicians can draw on a large body of evidence from clinical trials.

Article

A rare complication of infective endocarditis

Author:: A. Michael Lincoff, MD

Publish date: May 1, 2010

An 85-year-old woman presents with a 2-hour history of dyspnea, dizziness, generalized weakness, nausea, and diaphoresis. What is the cause?

Article

Prasugrel for acute coronary syndromes: Faster, more potent, but higher bleeding risk

Author:: A. Michael Lincoff, MD

Publish date: December 1, 2009

Prasugrel (Effient) is faster and more consistent in its effects, but patients at high bleeding risk should still receive clopidogrel (Plavix).

Article

GUSTO V: Combination drug treatment of acute myocardial infarction

Author:: A. Michael Lincoff, MD

Publish date: July 1, 2002

The combination of abciximab in full doses and reteplase in half doses was not superior to full-dose reteplase alone, but it was "not inferior" eit...

Article

Glycoprotein IIb/IIIa inhibitors in acute coronary syndromes

Author:: A. Michael Lincoff, MD

Publish date: February 1, 2000

These potent antiplatelet agents constitute a breakthrough, but questions remain about their safety, cost-effectiveness, and proper empiric use. Wi...